| 1728 |
National Cancer Institute |
Html |
en |
End-of-Life Care for People Who Have Cancer |
A fact sheet that answers some of the questions patients, their family members, and caregivers may have about the end of life. |
| family members | 0.618911 |
| family caregivers | 0.218961 |
| advance directives | 0.30098 |
| patients | 0.4187 |
| people | 0.36964 |
| life | 0.365064 |
| caregivers | 0.584429 |
|
| health care team | 0.768547 |
| person | 0.99495 |
| patient | 0.848579 |
| hospice care | 0.29663 |
| Related Resources section | 0.284122 |
| loved ones | 0.266236 |
| cancer | 0.462571 |
|
CLICK HERE |
| 1751 |
National Cancer Institute |
Html |
en |
Hospice Care |
A fact sheet about hospice care, including insurance coverage. |
| palliative care share | 0.4463 |
| home health | 0.436046 |
| hospice programs | 0.663338 |
| hospice team | 0.740949 |
| specific care decisions | 0.42786 |
| hospice doctor | 0.624846 |
| spiritual support | 0.408056 |
| public health departments | 0.391127 |
| American Cancer Society | 0.455655 |
| hospice services | 0.722561 |
| home health aides | 0.405139 |
| state Medicaid office | 0.402126 |
| nursing care | 0.391635 |
| hospice medical director | 0.768439 |
| Hospice Association | 0.649826 |
| cancer care | 0.409838 |
| hospital business office | 0.388593 |
| life expectancy | 0.408587 |
| hospice team member | 0.685192 |
| special in-patient facilities | 0.500987 |
| Medicare website | 0.415518 |
| specific state locations | 0.392604 |
| government health insurance | 0.402081 |
| sheet Palliative Care | 0.444628 |
| state social services | 0.40519 |
|
| nursing homes | 0.407681 |
| end-of-life care | 0.424373 |
| health aide services | 0.410795 |
| hospice organizations | 0.592662 |
| Palliative Care Organization | 0.507564 |
| private insurance plans | 0.399019 |
| Hospice Net | 0.623257 |
| palliative care | 0.604188 |
| Medicare coverage | 0.386456 |
| national hospice | 0.673933 |
| regional home health | 0.398589 |
| national hospice programs | 0.634262 |
| hospice care | 0.982488 |
| local state welfare | 0.391739 |
| health insurance plans | 0.419219 |
| Medicare benefits | 0.388255 |
| hospice expenses | 0.700651 |
| insurance plans | 0.503978 |
| federal-state partnership program | 0.389089 |
| Medicare Hospice Benefits | 0.695621 |
| Medicare-certified hospice programs | 0.660409 |
| Respite Care page | 0.429976 |
| social work services | 0.407475 |
| free fact sheets | 0.38648 |
|
CLICK HERE |
| 1910 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales. |
| tejido tumoral carcinoide | 0.303641 |
| electrodos minúsculos | 0.300961 |
| tumor carcinoide | 0.379006 |
| siguientes procedimientos | 0.32226 |
| pequeña cámara | 0.300969 |
| pequeña cantidad | 0.300995 |
| claro cuál | 0.301673 |
| rayos x | 0.301155 |
| tumores carcinoides gi | 0.541315 |
| cromogranina a | 0.301286 |
| ondas sonoras | 0.301178 |
| sÃndrome carcinoide | 0.405552 |
| pequeño efecto | 0.300747 |
| tumores neuroendocrinos | 0.31718 |
| National Cancer Institute | 0.300501 |
| tumores carcinoide gi | 0.305034 |
|
| siguientes riesgos | 0.300555 |
| endocrina múltiple tipo | 0.30275 |
| Instituto Nacional | 0.300956 |
| PDQ Tratamiento | 0.301284 |
| neurofibromatosis tipo | 0.301611 |
| tubo gi | 0.311684 |
| Physician Data Query | 0.302032 |
| pimientos chili | 0.300797 |
| carcinoides gi recidivantes | 0.302839 |
| Antecedentes familiares | 0.301159 |
| cuerpo cantidades | 0.303122 |
| hÃgado ayuda | 0.301344 |
| tumores carcinoides | 0.989957 |
| tumor carcinoide gi | 0.311705 |
| siguientes sumarios | 0.303432 |
| células neuroendocrinas | 0.30282 |
|
CLICK HERE |
| 1967 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pene (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pene. |
| siguientes procedimientos | 0.765966 |
| siguientes aspectos | 0.663436 |
| radiosensibilizadores ayuda | 0.608332 |
| estadio ii | 0.653561 |
| ganglio linfático centinela | 0.99757 |
| rayos x | 0.61452 |
| menor cantidad | 0.630187 |
| enlace drugs approved | 0.616023 |
| ondas sonoras | 0.614903 |
| National Cancer Institute | 0.60451 |
| siguientes riesgos | 0.604706 |
| papiloma virus | 0.656514 |
| únicos tratamientos | 0.60726 |
|
| Instituto Nacional | 0.609778 |
| Penile Cancer | 0.60882 |
| estadio iiia | 0.623114 |
| PDQ Tratamiento | 0.608893 |
| cuerpo esponjoso | 0.725663 |
| presente sección | 0.608144 |
| Physician Data Query | 0.620917 |
| siguientes sitios | 0.675658 |
| siguientes operaciones | 0.617884 |
| órgano masculino | 0.616691 |
| siguientes pruebas | 0.65372 |
| siguientes estadios | 0.621615 |
|
CLICK HERE |
| 2080 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de testículo (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de testículo. |
| estadios tardÃos | 0.651471 |
| Visuals Online | 0.570773 |
| PDQ Exámenes | 0.759721 |
| Physician Data Query | 0.918778 |
| testÃculos.ampliar anatomÃa | 0.643812 |
| mejores tratamientos | 0.631067 |
| prevención revisa | 0.590052 |
|
| sistema urinario masculino | 0.76274 |
| glándulas sexuales masculinas | 0.790025 |
| información ayuda | 0.600632 |
| National Cancer Institute | 0.62598 |
| siguientes riesgos | 0.575127 |
| Instituto Nacional | 0.738066 |
|
CLICK HERE |
| 3427 |
National Cancer Institute |
Html |
es |
Terapia láser para el tratamiento del cáncer |
Hoja informativa que describe el uso de una luz de alta intensidad en el tratamiento del cáncer, sus ventajas y desventajas, y los tipos de procedimientos que la utilizan. |
| usa calor | 0.497681 |
| luz solar | 0.504529 |
| terapia láser usa | 0.846675 |
| usa rayos | 0.615014 |
| sustancia fotosensibilizadora | 0.467924 |
|
| alta intensidad | 0.607112 |
| terapia láser causa | 0.851667 |
| áreas minúsculas | 0.473045 |
| determinados sÃntomas | 0.470796 |
|
CLICK HERE |
| 3599 |
National Cancer Institute |
Html |
en |
The RAS Initiative |
NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers. |
| new therapies | 0.393067 |
| RAS | 0.99043 |
| RAS family | 0.739708 |
| long way | 0.387894 |
| oncogenic RAS | 0.6688 |
| primary focus | 0.382845 |
| RAS problem | 0.663793 |
| industry | 0.314692 |
| videos | 0.313651 |
| mouse retroviruses | 0.388906 |
| lab | 0.314136 |
| percent | 0.362189 |
| online forum RAS | 0.726513 |
| RAS reagents | 0.661904 |
| Douglas R. Lowy | 0.440325 |
| RAS genes | 0.803577 |
| Varmus’s vision | 0.381489 |
| RAS hub | 0.667188 |
| entire field | 0.379292 |
| mutations | 0.318554 |
| RAS oncogenes | 0.710337 |
| proteins | 0.316387 |
| Dear Colleagues | 0.397967 |
| National Cancer Institute | 0.440589 |
|
| pancreatic cancers | 0.432526 |
| NCI director | 0.401396 |
| RAS-related cancers | 0.425588 |
| events | 0.31366 |
| group | 0.314948 |
| innovative approaches | 0.393563 |
| goal | 0.328772 |
| biology | 0.314898 |
| academic researchers | 0.385896 |
| RAS Central | 0.733488 |
| virtual network | 0.380109 |
| headway | 0.320561 |
| Dr. Harold Varmus | 0.45561 |
| blog posts | 0.37846 |
| ras initiative | 0.905093 |
| mutant forms | 0.396413 |
| scientists | 0.313674 |
| useful tools | 0.379773 |
| human cancers | 0.42887 |
| fascinating problem | 0.378178 |
| colorectal cancers | 0.432751 |
| concerted effort | 0.392419 |
| time | 0.314762 |
|
CLICK HERE |
| 3880 |
National Cancer Institute |
Html |
es |
Extractos de muérdago (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer. |
| from mistletoe extract | 0.31162 |
| Cancer Res Clin | 0.306787 |
| mistletoe extracts | 0.396569 |
| album extract isorel | 0.309539 |
| Mistletoe extracts standardised | 0.30709 |
| viscum album | 0.980886 |
| galactoside-specific lectin from | 0.335383 |
| thionins from viscum | 0.3152 |
| muérdago i | 0.308032 |
| treated with viscum | 0.312029 |
| Cancer Res | 0.31513 |
| isolated from viscum | 0.307496 |
| extracto viscum album | 0.308065 |
| Viscum album agglutinin-induced | 0.308373 |
| with viscum album | 0.33586 |
| from viscum album | 0.472392 |
| beta-galactoside-specific lectin from | 0.310754 |
| Hajto T | 0.314595 |
| extract from viscum | 0.316835 |
| Viscum album enhancing | 0.30854 |
| patients with | 0.307472 |
| thionins from european | 0.306901 |
| Immunomodulatory Agents from | 0.306741 |
| viscum album extract | 0.338924 |
| viscum album l | 0.601922 |
|
| Mistletoe lectins as | 0.306952 |
| preparation from viscum | 0.308802 |
| Complement Ther Med | 0.308742 |
| tumor cell | 0.31334 |
| Mistletoe extracts standardized | 0.30726 |
| Beuth J | 0.317637 |
| mistletoe treatment | 0.310143 |
| lectin from | 0.350339 |
| derived from viscum | 0.315008 |
| In vitro effects | 0.312037 |
| Schaller G | 0.307482 |
| blood mononuclear cells | 0.315901 |
| subspecies viscum album | 0.308835 |
| lectin from viscum | 0.322905 |
| Gabius HJ | 0.329931 |
| Viscum album induces | 0.316269 |
| ml1 from viscum | 0.307567 |
| breast cancer | 0.326075 |
| Viscum album species | 0.308916 |
| plant lectin | 0.306716 |
| mistletoe lectins | 0.449053 |
| in vitro | 0.456679 |
| Hostanska K | 0.309958 |
| fermented extract from | 0.30821 |
|
CLICK HERE |
| 15645 |
National Cancer Institute |
Html |
en |
Legal Requirements |
Research grants are subject to many requirements from a variety of legal authorities, with the broadest being the U.S. Constitution. |
| Grants Management Officer | 0.556816 |
| United States Code | 0.420323 |
| research grants | 0.615532 |
| basic substantive legislation | 0.444546 |
| program requirements | 0.352641 |
| to-date policy guidance | 0.408228 |
| general regulations | 0.340444 |
| federal agency | 0.352362 |
| federal regulations | 0.501493 |
| Administrative Procedures Act | 0.389735 |
| NIH standard terms | 0.534403 |
| NIH Grants Policy | 0.868204 |
| research grant policies | 0.404926 |
| reasonable conditions | 0.340026 |
| research community | 0.390073 |
| appropriation legislation | 0.37075 |
| individual grants | 0.462407 |
| Appropriation bills | 0.343865 |
| NIH contracting offices | 0.525598 |
| legal authorities | 0.328189 |
| issues government-wide circulars | 0.425727 |
| administrative requirements | 0.328069 |
| NCI grants | 0.592028 |
| human subjects protection | 0.399778 |
| grants administration policies | 0.567751 |
|
| Congress | 0.346023 |
| authorize federal agencies | 0.500849 |
| United States | 0.452601 |
| CFR Parts | 0.368971 |
| grants administration decisions | 0.591481 |
| federal Executive agencies | 0.452185 |
| CFR | 0.384291 |
| appropriation laws | 0.351099 |
| Spending Power Clause | 0.442228 |
| United States Constitution | 0.43014 |
| grants administration | 0.689773 |
| grants area | 0.524071 |
| appropriate NIH oversight | 0.528865 |
| grants | 0.962134 |
| program expenditures | 0.33855 |
| requirements | 0.388492 |
| NIH Guide | 0.647123 |
| federal register | 0.490568 |
| federal assistance funds | 0.682098 |
| specific laws | 0.335616 |
| specific program | 0.335203 |
| federal program | 0.371737 |
| Public Health Service | 0.421913 |
| general authority | 0.329535 |
|
CLICK HERE |
| 16162 |
National Cancer Institute |
Html |
en |
New Therapies Are Changing the Outlook for Advanced Melanoma |
An article about a host of new treatment options that have been produced in the last several years for patients with the skin cancer melanoma. |
| improved progression-free survival | 0.366558 |
| new therapies | 0.351845 |
| target BRAF proteins | 0.357172 |
| commonly used therapies | 0.342946 |
| BRAF inhibitor | 0.43187 |
| BRAF mutations | 0.802264 |
| Cancer Therapy Evaluation | 0.357896 |
| Overall survival results | 0.381093 |
| Dr. Schuchter | 0.658164 |
| overall survival | 0.53856 |
| clinical trials | 0.561097 |
| results | 0.412771 |
| median progression-free survival | 0.364224 |
| clinical trial | 0.629151 |
| median overall survival | 0.359384 |
| patients | 0.941423 |
| recent FDA-approved drugs | 0.349384 |
| tumor responses | 0.376799 |
| metastatic melanoma | 0.378989 |
| chemotherapy drug dacarbazine | 0.34213 |
| median survival | 0.400006 |
| melanoma specialist | 0.389264 |
| large clinical trial | 0.469476 |
| MEK inhibitor | 0.413513 |
|
| cancer cells | 0.348742 |
| Patient tumor samples | 0.353483 |
| skin-related side effects | 0.386676 |
| MEK inhibitor cobimetinib | 0.40543 |
| clinical trial participants | 0.357541 |
| BRAF-MEK inhibitor combination | 0.3755 |
| Dr. Streicher | 0.487979 |
| tumor cells | 0.429743 |
| checkpoint inhibitor | 0.371337 |
| small clinical trials | 0.342687 |
| drugs | 0.41439 |
| progression-free survival | 0.707667 |
| MEK inhibitors | 0.605005 |
| advanced melanoma | 0.87481 |
| PD-1 inhibitor | 0.342866 |
| recent clinical trials | 0.345485 |
| new treatment options | 0.457424 |
| tumors | 0.426135 |
| New Melanoma Therapies | 0.48664 |
| early-phase clinical trial | 0.367414 |
| Moffitt Cancer Center | 0.358773 |
| regulatory approval | 0.407964 |
| Pennsylvania Abramson Cancer | 0.343564 |
| skin cancer melanoma | 0.49678 |
|
CLICK HERE |